Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 374

1.

Fracture risk in men with prostate cancer: a population-based study.

Melton LJ 3rd, Lieber MM, Atkinson EJ, Achenbach SJ, Zincke H, Therneau TM, Khosla S.

J Bone Miner Res. 2011 Aug;26(8):1808-15. doi: 10.1002/jbmr.405.

2.

Long-term outcome of ureterosigmoidostomy: an analysis of patients with >10 years of follow-up.

Tollefson MK, Elliott DS, Zincke H, Frank I.

BJU Int. 2010 Mar;105(6):860-3. doi: 10.1111/j.1464-410X.2009.08811.x. Epub 2009 Aug 13.

3.

Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy.

Pisters LL, Leibovici D, Blute M, Zincke H, Sebo TJ, Slezak JM, Izawa J, Ward JF, Scott SM, Madsen L, Spiess PE, Leibovich BC.

J Urol. 2009 Aug;182(2):517-25; discussion 525-7. doi: 10.1016/j.juro.2009.04.006. Epub 2009 Jun 13.

PMID:
19524984
4.

Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer.

Chrouser K, Leibovich B, Bergstralh E, Zincke H, Blute M.

J Urol. 2008 May;179(5 Suppl):S7-S11. doi: 10.1016/j.juro.2008.03.131.

PMID:
18405759
5.

How long is too long? The effect of the duration of anaesthesia on the incidence of non-urological complications after surgery.

Routh JC, Bacon DR, Leibovich BC, Zincke H, Blute ML, Frank I.

BJU Int. 2008 Aug;102(3):301-4. doi: 10.1111/j.1464-410X.2008.07663.x. Epub 2008 Apr 11.

6.

After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.

Sengupta S, Blute ML, Bagniewski SM, Inman B, Leibovich BC, Slezak JM, Myers RP, Zincke H.

BJU Int. 2008 Jan;101(2):170-4. doi: 10.1111/j.1464-410X.2007.07270.x.

7.

Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases.

Molina JR, Quevedo JF, Furth AF, Richardson RL, Zincke H, Burch PA.

Cancer. 2007 Dec 1;110(11):2434-40.

8.

Treatment of prostate cancer local recurrence after radical retropubic prostatectomy with 17-gauge interstitial transperineal cryoablation: initial experience.

Siddiqui SA, Mynderse LA, Zincke H, Hoffmann NE, Lobo JR, Wilson TM, Kawashima A, Davis BJ, Blute ML.

Urology. 2007 Jul;70(1):80-5.

PMID:
17656213
9.

Endoscopic management of upper tract urothelial carcinoma in patients with a history of bladder urothelial carcinoma.

Krambeck AE, Thompson RH, Lohse CM, Patterson DE, Segura JW, Zincke H, Elliott DS, Blute ML.

J Urol. 2007 May;177(5):1721-6.

PMID:
17437796
10.

Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.

Tollefson MK, Slezak JM, Leibovich BC, Zincke H, Blute ML.

Mayo Clin Proc. 2007 Apr;82(4):422-7.

PMID:
17418069
11.

Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score.

Thompson RH, Leibovich BC, Lohse CM, Cheville JC, Zincke H, Blute ML, Frank I.

J Urol. 2007 Feb;177(2):477-80.

PMID:
17222614
12.

The impact of ischemia time during open nephron sparing surgery on solitary kidneys: a multi-institutional study.

Thompson RH, Frank I, Lohse CM, Saad IR, Fergany A, Zincke H, Leibovich BC, Blute ML, Novick AC.

J Urol. 2007 Feb;177(2):471-6.

PMID:
17222613
13.

Impact of tumor size on the predictive ability of the pT3a primary tumor classification for renal cell carcinoma.

Siddiqui SA, Frank I, Leibovich BC, Cheville JC, Lohse CM, Zincke H, Blute ML.

J Urol. 2007 Jan;177(1):59-62.

PMID:
17162000
14.

The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma.

Krambeck AE, Leibovich BC, Lohse CM, Kwon ED, Zincke H, Blute ML.

J Urol. 2006 Nov;176(5):1990-5; discussion 1995.

PMID:
17070231
15.

Outcomes of Gleason score 10 prostate carcinoma treated by radical prostatectomy.

Inman BA, DiMarco DS, Slezak JM, Sebo TJ, Kwon ED, Leibovich BC, Blute ML, Zincke H.

Urology. 2006 Sep;68(3):604-8. Epub 2006 Sep 18.

PMID:
16979719
16.

Is nephron-sparing surgery for small renal masses underused?

Sengupta S, Zincke H.

Nat Clin Pract Urol. 2006 Aug;3(8):412-3. No abstract available.

PMID:
16902513
17.

Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy.

Siddiqui SA, Sengupta S, Slezak JM, Bergstralh EJ, Zincke H, Blute ML.

J Urol. 2006 Sep;176(3):1118-21.

PMID:
16890705
18.

Second primary malignancies associated with renal cell carcinoma histological subtypes.

Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED, Zincke H, Blute ML.

J Urol. 2006 Sep;176(3):900-3; discussion 903-4.

PMID:
16890648
19.

Conventional assessment of needle biopsy specimens is more useful than digital image analysis of proliferation and DNA ploidy in prediction of positive surgical margins at radical prostatectomy.

Sengupta S, Cheville JC, Lohse CM, Zincke H, Myers RP, Riehle DL, Pankratz VS, Blute ML, Sebo TJ.

Urology. 2006 Jul;68(1):94-8.

PMID:
16844452
20.

Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy.

Ashley RA, Inman BA, Sebo TJ, Leibovich BC, Blute ML, Kwon ED, Zincke H.

Cancer. 2006 Aug 15;107(4):712-20.

21.

Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.

Sengupta S, Christensen CM, Zincke H, Slezak JM, Leibovich BC, Bergstralh EJ, Myers RP, Blute ML.

J Urol. 2006 Aug;176(2):559-63.

PMID:
16813889
22.

Obesity and survival after radical prostatectomy: A 10-year prospective cohort study.

Siddiqui SA, Inman BA, Sengupta S, Slezak JM, Bergstralh EJ, Leibovich BC, Zincke H, Blute ML.

Cancer. 2006 Aug 1;107(3):521-9.

23.

Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001.

Sengupta S, Slezak JM, Blute ML, Leibovich BC, Sebo TJ, Myers RP, Cheville JC, Bergstralh EJ, Zincke H.

Cancer. 2006 Jun 15;106(12):2630-5.

24.

Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival.

Sengupta S, Blute ML, Bagniewski SM, Myers RP, Bergstralh EJ, Leibovich BC, Zincke H.

J Urol. 2006 May;175(5):1684-90; discussion 1690.

PMID:
16600730
25.

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon ED.

Cancer Res. 2006 Apr 1;66(7):3381-5.

26.

Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer.

Siddiqui SA, Sengupta S, Slezak JM, Bergstralh EJ, Leibovich BC, Myers RP, Zincke H, Blute ML.

J Urol. 2006 Mar;175(3 Pt 1):952-7.

PMID:
16469591
27.
28.

Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma.

Sengupta S, Cheville JC, Corless CL, Lohse CM, Heinrich MC, Kwon ED, Zincke H, Blute ML, Leibovich BC.

J Urol. 2006 Jan;175(1):53-6.

PMID:
16406868
29.

The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma.

Sengupta S, Lohse CM, Cheville JC, Leibovich BC, Thompson RH, Webster WS, Frank I, Zincke H, Blute ML, Kwon ED.

Cancer. 2006 Jan 15;106(2):304-12.

30.

Is radical prostatectomy of benefit in men with localized prostate cancer?

Sengupta S, Zincke H.

Nat Clin Pract Oncol. 2005 Dec;2(12):608-9. No abstract available.

PMID:
16341112
31.

Re: The accuracy of 250 fine needle biopsies of renal tumors.

Sengupta S, Zincke H, Blute ML.

J Urol. 2005 Dec;174(6):2422; author reply 2422. No abstract available.

PMID:
16280865
32.

Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.

Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML.

J Urol. 2005 Dec;174(6):2191-6.

PMID:
16280762
33.

A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.

Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED, Merchan JR, Blute ML.

J Urol. 2005 Nov;174(5):1759-63; discussion 1763.

PMID:
16217278
34.

Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma.

Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Chen L, Zincke H, Blute ML, Leibovich BC, Kwon ED.

Cancer. 2005 Nov 15;104(10):2084-91.

35.

Lessons learned in the surgical management of renal cell carcinoma.

Sengupta S, Zincke H.

Urology. 2005 Nov;66(5 Suppl):36-42. Review.

PMID:
16194705
36.

Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma?

Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED, Frank I, Zincke H, Blute ML.

J Urol. 2005 Oct;174(4 Pt 1):1218-21.

PMID:
16145373
37.

Complications of contemporary open nephron sparing surgery: a single institution experience.

Thompson RH, Leibovich BC, Lohse CM, Zincke H, Blute ML.

J Urol. 2005 Sep;174(3):855-8.

PMID:
16093969
38.

Surgery for metastatic renal cell cancer.

Sengupta S, Leibovich BC, Blute ML, Zincke H.

World J Urol. 2005 Jul;23(3):155-60. Epub 2005 Jun 30. Review.

PMID:
15988593
39.

Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness.

Sengupta S, Lohse CM, Leibovich BC, Frank I, Thompson RH, Webster WS, Zincke H, Blute ML, Cheville JC, Kwon ED.

Cancer. 2005 Aug 1;104(3):511-20.

40.

Surgical treatment of stage pT3b renal cell carcinoma in solitary kidneys: a case series.

Sengupta S, Zincke H, Leibovich BC, Blute ML.

BJU Int. 2005 Jul;96(1):54-7.

41.

Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer.

Chrouser K, Leibovich B, Bergstralh E, Zincke H, Blute M.

J Urol. 2005 Jul;174(1):107-10; discussion 110-1.

PMID:
15947588
42.

Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy.

Thompson RH, Cheville JC, Lohse CM, Webster WS, Zincke H, Kwon ED, Frank I, Blute ML, Leibovich BC.

Cancer. 2005 Jul 1;104(1):53-60.

43.

Urinary fistulas following external radiation or permanent brachytherapy for the treatment of prostate cancer.

Chrouser KL, Leibovich BC, Sweat SD, Larson DW, Davis BJ, Tran NV, Zincke H, Blute ML.

J Urol. 2005 Jun;173(6):1953-7.

PMID:
15879789
44.

Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses.

Gillett MD, Cheville JC, Karnes RJ, Lohse CM, Kwon ED, Leibovich BC, Zincke H, Blute ML.

J Urol. 2005 Jun;173(6):1893-6.

PMID:
15879770
45.
46.

Intraperitoneal drop metastasis after radiofrequency ablation of pararenal tumor recurrences.

Krambeck AE, Farrell MA, Charboneau JW, Frank I, Zincke H.

Urology. 2005 Apr;65(4):797.

PMID:
15833533
47.
48.

Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes.

Ward JF, Sebo TJ, Blute ML, Zincke H.

J Urol. 2005 Apr;173(4):1156-60.

PMID:
15758726
49.

The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.

DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ, Blute ML.

J Urol. 2005 Apr;173(4):1121-5.

PMID:
15758719
50.

Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a?

Thompson RH, Leibovich BC, Cheville JC, Lohse CM, Frank I, Kwon ED, Zincke H, Blute ML.

J Urol. 2005 Mar;173(3):918-21.

PMID:
15711327

Supplemental Content

Loading ...
Support Center